FDA-Drug2026-09-09Class IIIMISBRANDING
American Health Packaging buprenorphine tablets recalled for label mix-up
What this means
American Health Packaging distributed buprenorphine sublingual tablets with incorrect labeling. The affected medication is a prescription opioid used to treat pain and opioid use disorder. A label mix-up could result in dosing errors if patients or healthcare providers rely on incorrect information.
- Check if your buprenorphine matches Lot #1030023 with expiration date 06/30/2027 and NDC #60687-481-21.
- Do not use affected tablets without speaking to your pharmacist or doctor first.
- Contact your pharmacy or healthcare provider for guidance on obtaining correctly labeled medication.
- Do not stop taking buprenorphine abruptly without medical supervision.
The agency's original wording
Hazard
Labeling: Label Mix-up
Intended for
Adults
Illnesses reported
None reported
Sold states
US Nationwide.
Affected count
10,953 cartons.
Manufactured in
2550 John Glenn Ave Ste A, N/A, Columbus, OH, United States
Products
Buprenorphine Sublingual Tablets (C-III), 2 mg, 30 Tablets (3x10), Rx only, Distributed by: American Health Packaging, Columbus, Ohio 43217, Carton NDC#: 60687-481-21, (Individual Dose NDC: 60687-481-11).
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0840-2026Want us to check the next one for you?
We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.